Towards the Development of a Pediatric Ventricular Assist Device

The very limited options available to treat ventricular failure in children with congenital and acquired heart diseases have motivated the development of a pediatric ventricular assist device at the University of Pittsburgh (UoP) and University of Pittsburgh Medical Center (UPMC). Our effort involve...

Full description

Saved in:
Bibliographic Details
Published in:Cell transplantation 2006-01, Vol.15 (1_suppl), p.69-74
Main Authors: Borovetz, Harvey S., Badylak, Stephen, Boston, J. Robert, Johnson, Carl, Kormos, Robert, Kameneva, Marina V., Simaan, Marwan, Snyder, Trevor A., Tsukui, Hiro, Wagner, William R., Woolley, Joshua, Antaki, James, Diao, Chenguang, Vandenberghe, Stijn, Keller, Bradley, Morell, Victor, Wearden, Peter, Webber, Steven, Gardiner, Jeff, Li, Chung M., Paden, Dave, Paden, Bradley, Snyder, Shaun, Wu, Jingchun, Bearnson, Gill, Hawkins, John A., Jacobs, Gordon, Kirk, John, Khanwilkar, Pratap, Kouretas, Peter C., Long, James, Shaddy, R. E.
Format: Article
Language:English
Subjects:
Biocompatible Materials
Child
Extracorporeal Membrane Oxygenation
Heart-Assist Devices
Humans
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The very limited options available to treat ventricular failure in children with congenital and acquired heart diseases have motivated the development of a pediatric ventricular assist device at the University of Pittsburgh (UoP) and University of Pittsburgh Medical Center (UPMC). Our effort involves a consortium consisting of UoP, Children's Hospital of Pittsburgh (CHP), Carnegie Mellon University, World Heart Corporation, and LaunchPoint Technologies, Inc. The overall aim of our program is to develop a highly reliable, biocompatible ventricular assist device (VAD) for chronic support (6 months) of the unique and high-risk population of children between 3 and 15 kg (patients from birth to 2 years of age). The innovative pediatric ventricular assist device we are developing is based on a miniature mixed flow turbodynamic pump featuring magnetic levitation, to assure minimal blood trauma and risk of thrombosis. This review article discusses the limitations of current pediatric cardiac assist treatment options and the work to date by our consortium toward the development of a pediatric VAD.
ISSN:0963-6897
1555-3892
DOI:10.3727/000000006783982304